{"name":"Hikma Pharmaceuticals","slug":"hikma","ticker":"HIK.L","exchange":"LSE","domain":"hikma.com","description":"Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.","hq":"London, UK / Amman, Jordan","founded":1978,"employees":"9400","ceo":"Riad Mishlawi","sector":"Generics / Injectables / Branded MENA","stockPrice":1311.5,"stockChange":26,"stockChangePercent":2.02,"marketCap":"$2.8B","metrics":{"revenue":3348999936,"revenueGrowth":8.5,"grossMargin":43.5,"rdSpend":0,"netIncome":402000000,"cash":243000000,"dividendYield":4.75,"peRatio":9.6,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Revex","genericName":"NALMEFENE","slug":"nalmefene","revenue":400000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"1948-01-01","label":"Norgesic first approved","drug":"Norgesic","drugSlug":"caffeine","type":"approval","sentiment":"positive"},{"date":"1957-01-01","label":"Robaxin first approved","drug":"Robaxin","drugSlug":"methocarbamol","type":"approval","sentiment":"positive"},{"date":"1960-01-01","label":"Hydrocortisone And Acetic Acid first approved","drug":"Hydrocortisone And Acetic Acid","drugSlug":"acetic-acid","type":"approval","sentiment":"positive"},{"date":"1965-01-01","label":"Dopram first approved","drug":"Dopram","drugSlug":"doxapram","type":"approval","sentiment":"positive"},{"date":"1979-01-01","label":"Reglan first approved","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"approval","sentiment":"positive"},{"date":"1979-01-01","label":"Reglan first approved","drug":"Reglan","drugSlug":"metoclopramide","type":"approval","sentiment":"positive"},{"date":"1980-01-01","label":"Lithium Citrate first approved","drug":"Lithium Citrate","drugSlug":"lithium-citrate","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Revex first approved","drug":"Revex","drugSlug":"nalmefene","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-01","label":"Onureg Phase 2 readout (Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma)","drug":"Onureg","drugSlug":"onureg","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-07-31","label":"Onureg Phase 2 readout (Myelodysplastic Syndromes)","drug":"Onureg","drugSlug":"onureg","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-12-22","label":"Reglan patent expiry (Method of Use)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-22","label":"Reglan patent expiry (Method of Use)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-22","label":"Reglan patent expiry (Method of Use)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-22","label":"Reglan patent expiry (Formulation)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2029-12-22","label":"Reglan patent expiry (Formulation)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2030-05-16","label":"Reglan patent expiry (Formulation)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2038-11-17","label":"Reglan patent expiry (Method of Use)","drug":"Reglan","drugSlug":"metoclopramide-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2044-10-09","label":"Robaxin patent expiry (Formulation)","drug":"Robaxin","drugSlug":"methocarbamol","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Doxil patent cliff ($150M at risk)","drug":"Doxil","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Pulmicort patent cliff ($100M at risk)","drug":"Pulmicort","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":400000000,"percentOfTotal":100,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Revex","genericName":"NALMEFENE","slug":"nalmefene","indication":"Alcoholism","status":"marketed","revenue":400000000},{"name":"Norgesic","genericName":"caffeine","slug":"caffeine","indication":"Allergic rhinitis","status":"marketed"},{"name":"Lithium Citrate","genericName":"LITHIUM CITRATE","slug":"lithium-citrate","indication":"Bipolar affective disorder, current episode manic","status":"marketed"},{"name":"Dopram","genericName":"DOXAPRAM","slug":"doxapram","indication":"Decreased respiratory function","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Reglan","genericName":"Metoclopramide Hydrochloride","slug":"metoclopramide-hydrochloride","indication":"Chemotherapy-induced nausea and vomiting","status":"marketed"},{"name":"Reglan","genericName":"METOCLOPRAMIDE","slug":"metoclopramide","indication":"Chemotherapy-induced nausea and vomiting","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Carcemia","genericName":"Carcemia","slug":"carcemia","indication":"Other","status":"phase_2"},{"name":"Onureg","genericName":"Onureg","slug":"onureg","indication":"Other","status":"discontinued"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Biosimilar Infliximab","genericName":"Biosimilar Infliximab","slug":"biosimilar-infliximab","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Hydrocortisone And Acetic Acid","genericName":"ACETIC ACID","slug":"acetic-acid","indication":"Superficial external auditory canal infections","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Robaxin","genericName":"METHOCARBAMOL","slug":"methocarbamol","indication":"Muscle Spasm with Pain","status":"marketed"}]}],"pipeline":[{"name":"Revex","genericName":"NALMEFENE","slug":"nalmefene","phase":"marketed","mechanism":"Kappa-type opioid receptor","indications":["Alcoholism","Opiate-Induced Respiratory Depression","Poisoning by opiate analgesic drug"],"catalyst":""},{"name":"Reglan","genericName":"Metoclopramide Hydrochloride","slug":"metoclopramide-hydrochloride","phase":"marketed","mechanism":"Metoclopramide stimulates upper GI tract motility by sensitizing tissues to acetylcholine action.","indications":["Chemotherapy-induced nausea and vomiting","Diabetic gastroparesis","Gastroesophageal reflux disease","Gastrointestinal Radiography Adjunct","Intubation of gastrointestinal tract"],"catalyst":""},{"name":"Norgesic","genericName":"caffeine","slug":"caffeine","phase":"marketed","mechanism":"Adenosine receptor A2a","indications":["Allergic rhinitis","Apnea in the newborn","Backache","Cluster Headache Prevention","Cluster headache syndrome"],"catalyst":""},{"name":"Lithium Citrate","genericName":"LITHIUM CITRATE","slug":"lithium-citrate","phase":"marketed","mechanism":"Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes.","indications":["Bipolar affective disorder, current episode manic","Bipolar disorder","Bipolar disorder in remission"],"catalyst":""},{"name":"Biosimilar Infliximab","genericName":"Biosimilar Infliximab","slug":"biosimilar-infliximab","phase":"marketed","mechanism":"Biosimilar infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Carcemia","genericName":"Carcemia","slug":"carcemia","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dopram","genericName":"DOXAPRAM","slug":"doxapram","phase":"marketed","mechanism":"Cytochrome P450 2D6","indications":["Decreased respiratory function","Post-Anesthesia Respiratory Depression"],"catalyst":""},{"name":"Hydrocortisone And Acetic Acid","genericName":"ACETIC ACID","slug":"acetic-acid","phase":"marketed","mechanism":"Tyrosine-protein kinase Lck","indications":["Superficial external auditory canal infections"],"catalyst":""},{"name":"Onureg","genericName":"Onureg","slug":"onureg","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Reglan","genericName":"METOCLOPRAMIDE","slug":"metoclopramide","phase":"marketed","mechanism":"D(3) dopamine receptor","indications":["Chemotherapy-induced nausea and vomiting","Diabetic gastroparesis","Gastroesophageal reflux disease","Gastrointestinal Radiography Adjunct","Intubation of gastrointestinal tract"],"catalyst":""},{"name":"Robaxin","genericName":"METHOCARBAMOL","slug":"methocarbamol","phase":"marketed","mechanism":"Carbonic anhydrase 1","indications":["Muscle Spasm with Pain","Spasticity","Tetanus Adjunct Treatment"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Hikma Pharmaceuticals reports strong Q4 2023 results","summary":"Hikma Pharmaceuticals reported strong Q4 2023 results, with revenue increasing 12% year-over-year to $1.1 billion.","drugName":"","sentiment":"positive"},{"date":"2023-09-06","type":"deal","headline":"Hikma Pharmaceuticals acquires US-based injectables manufacturer","summary":"Hikma Pharmaceuticals acquired US-based injectables manufacturer, Hi-Tech Pharmacal, for $1.1 billion.","drugName":"","sentiment":"positive"},{"date":"2023-05-25","type":"regulatory","headline":"Hikma Pharmaceuticals receives FDA approval for generic version of blockbuster medication","summary":"Hikma Pharmaceuticals received FDA approval for a generic version of the blockbuster medication, which is used to treat a range of conditions, including high blood pressure and heart failure.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQYThWZFFUeFhvZU5tdFcwaUpNNU9sckVDeFB1UnR3c0tMUG9OdkZlR3dCLWpOeW50WHZWUm1KRjhJY0pzT01ZSEpXX1lYRTc0RklxZkhCeXNTdVQzMmNhZW0zVzdZV2g5ekJFbnFJamc4dWE4UG1ENkpoTFZueDlwV2FyMXpMQkJJbHEyZ2F3?oc=5","date":"2026-02-26","type":"deal","source":"Yahoo Finance UK","summary":"Hikma Pharma tumbles on softer guidance as buyback fails to soften pill - Yahoo Finance UK","headline":"Hikma Pharma tumbles on softer guidance as buyback fails to soften pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPeVFrb0JZRUJHN29WTTRVYjF3bTQyQ0pIMmZZZjdRdXdFa1NaaXY0VWlfaC1hQzR0TE1HdUtrMHNuZDNqZVZnYm1TMW5nemVWV0hoc1h5Q3ZPNHlXcDRBV3h3ZUQxSDZrUG84ckE3YU1vMGlqQnlWRDNaV1UtU19qWmkySVdOem1EZFpOZnZvTmxaNGRqbnI2dmhEVG9BMThXSjVmYy04c1pFRGRaWTgwSG5kUHdWXzMxZ2VrRlJudEVnTy1mZGlaUDRSM3dlVWY0VEE?oc=5","date":"2026-02-26","type":"pipeline","source":"Reuters","summary":"Hikma Pharma's gloomy outlook kicks shares to more than three-year low - Reuters","headline":"Hikma Pharma's gloomy outlook kicks shares to more than three-year low","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQcXJySXd1eFhzdmQtVXprMURWVHZvaml3cHdsLXNzRWlpTTF2eTYzRWstZklrYTNLTzFyS1VOaUJkSU5iaUd4enRyaTI1T2lMVTF5YXMwcWZkanMydkZaSEVBeTRzcVBkbUc2aDVxcXJyVlMwZnlmdXZUcXQyeG9KRFp1QQ?oc=5","date":"2025-10-01","type":"deal","source":"Yahoo Finance UK","summary":"Pharma Stocks Drive FTSE 100 Higher Amid Pfizer-US Deal - Yahoo Finance UK","headline":"Pharma Stocks Drive FTSE 100 Higher Amid Pfizer-US Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNV1k0VXFOQWgyNmY5b19FUmlhczZSU0FDalZtcjFyVk40MFY3N181Y2FpSWE4ZnZ4Q3ZTZ3lfVHBycE1vRk1Mbmx4d09RZHFnU3EzZktWbW1kRy1jdkcxRUxhYVVyaU1TaWFPVmowWEN3SE85UDY3WWFRZUxqZEpEQXozVXNkWWhXNG1zTS1CNVd1VGFraHFtR3VjRTFfVllsandEb0s2YlNSLUZpSUw5NTlveTJBTG1jbGc?oc=5","date":"2025-05-08","type":"pipeline","source":"Reuters","summary":"Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters","headline":"Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPOUFDbG45OTluSjAwZ1dnQ0p6THd0UHg2UGd1SXo5TmtBU0xpRG1BS3h4bjVRTF9BODhfa1V6YVpzRnBDUUNBZVhQV3dIS0JQVnF1UXRsdXBjUE40Q1VCclcwSk9McHlOMGFtTGN5V0xiRVowT0FlbjdoWnZhRE9uMTZXdFR0UHhlYzVwY2RCcFNVOTVDeVZOTkhoWXJFME9PQVdRR3lCaG1uV3hmTFE?oc=5","date":"2024-02-01","type":"pipeline","source":"Reuters","summary":"Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million - Reuters","headline":"Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNZnRYbW5zcnFfNGVLYjhYaG5UOWxJUDFYYVV5aV9sNVoxSmpfVVJNUjVaaE9sclg4cllvLXV1ZDdrSEZyM19senRabklkZ3VUV2NHaGZvd0xCdWstLU4tNWtEZ1EzdXh0WVkwM2l1WV94cnRBTkUxNGFYZzF1S2xzZTB6dHpfNmM?oc=5","date":"2023-05-07","type":"pipeline","source":"London South East","summary":"Hikma Pharmaceuticals Share Price (HIK) - London South East","headline":"Hikma Pharmaceuticals Share Price (HIK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUUJCOTlwWjlXVUs4X1lBeXJnNTZZMmNrVWlseXdUMFNPNmZpZmNJcDJMeW1BeVIwdHNNZ2pPbkxvYkxEXzBKQkFBaG51WGllMjZOaE1fTEpYN3ZUaTlxZ2RDcVRUVDRkMkh4MlZveDJUajBnWXowS2p2Z2p4MUZiUVNpb3ZOY3c3ZlNpOERzZGNpdi1pRHFXc080NGxYVmFHM1U3OFBSTVp2TF9qQUxaaWx1bVlQc2pNbUFreURlQnBJNHM?oc=5","date":"2023-02-23","type":"pipeline","source":"RTTNews","summary":"Hikma Pharma FY22 Results Down, Lifts Dividend; Says Confident Of FY23 Growth; Stock Up - RTTNews","headline":"Hikma Pharma FY22 Results Down, Lifts Dividend; Says Confident Of FY23 Growth; Stock Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQbXVEQzVIdWZaeUI4eVhlSlVMN2FweUdSVzdiZVY4UVpFcWVqUFZoM1ZjZ3M2M3dFUndPeDFTU1JCMTZfdklsYWF0Y0EweFVtSmxzVFpHVDR0OTY1QkdtbGE2dE9Ca1FmSmNsTXpXWExSWFpEQ3V3MzBxNjRkOEE5cTRuWWFLT0dOdW1pT1BBRllMUTFpZXpXX0pyQ0k?oc=5","date":"2022-02-24","type":"earnings","source":"RTTNews","summary":"Hikma Pharma FY21 Profit Down, Lifts Dividend; Stock Down - RTTNews","headline":"Hikma Pharma FY21 Profit Down, Lifts Dividend; Stock Down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNanRDbGx1aHhEVmxUM2hGczNNTG5nZklzTXNhOENCS1czcVFCYVJRYlI5elFKZlREaEljWEFfc0FqcWNqeDd6VklEZTdwUTBpd0w4N1hubDFLOE1mUzdicW1aa3JsXzBIRXZQX2t2WmhoSlR6UjlKSTVxVnNZQTYwS3ptZDZqUV9jU0N3R2NRREdmdVdlbUE?oc=5","date":"2018-07-22","type":"pipeline","source":"Hargreaves Lansdown","summary":"Hikma Pharmaceuticals Share Price (HIK) Ordinary GBP 0.10 | HIK - Hargreaves Lansdown","headline":"Hikma Pharmaceuticals Share Price (HIK) Ordinary GBP 0.10 | HIK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE4zajJIbFJyZDFQSmtaQVpzR296Ym1wU3BjU0NOVmN4QjJVM0ZTa21BS2syWGtQSU5DWXY0UVpQQkFwTk1RcG8yNVlMWm9HX09RLXRlQm05R3Q4WjkwakFtZjdyS0ZXU1pVRTdqVw?oc=5","date":"2015-09-04","type":"pipeline","source":"Pharmacy Times","summary":"West-Ward Pharmaceuticals - Pharmacy Times","headline":"West-Ward Pharmaceuticals","sentiment":"neutral"}],"patents":[{"drugName":"Doxil","drugSlug":"doxorubicin-hydrochloride-liposome","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":150000000},{"drugName":"Pulmicort","drugSlug":"budesonide","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"11020361","type":"Method of Use","expiryDate":"2029-12-22","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"12194009","type":"Method of Use","expiryDate":"2029-12-22","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"12194008","type":"Method of Use","expiryDate":"2029-12-22","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"11628150","type":"Formulation","expiryDate":"2029-12-22","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"11813231","type":"Formulation","expiryDate":"2029-12-22","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"8334281","type":"Formulation","expiryDate":"2030-05-16","territory":"US","genericFilings":[]},{"drugName":"Reglan","drugSlug":"metoclopramide-hydrochloride","patentNumber":"12377064","type":"Method of Use","expiryDate":"2038-11-17","territory":"US","genericFilings":[]},{"drugName":"Robaxin","drugSlug":"methocarbamol","patentNumber":"12390439","type":"Formulation","expiryDate":"2044-10-09","territory":"US","genericFilings":[]}],"drugCount":11,"phaseCounts":{"marketed":9,"phase_2":1,"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Teva Pharmaceutical Industries","Mylan N.V.","Sandoz International GmbH"],"therapeuticFocus":["Oncology","Infectious Diseases","Cardiovascular Diseases"],"financials":null,"yahoo":{"currentPrice":1311.5,"previousClose":1285.5,"fiftyTwoWeekHigh":2164,"fiftyTwoWeekLow":1187,"fiftyTwoWeekRange":"1187.0 - 2164.0","fiftyDayAverage":1398.76,"twoHundredDayAverage":1639.95,"beta":0.61,"enterpriseValue":4203474432,"forwardPE":7,"priceToBook":147.42,"priceToSales":0.85,"enterpriseToRevenue":1.25,"enterpriseToEbitda":4.99,"pegRatio":0,"ebitda":842000000,"ebitdaMargin":25.1,"freeCashflow":-66125000,"operatingCashflow":436000000,"totalDebt":1604000000,"debtToEquity":61.5,"currentRatio":1.82,"returnOnAssets":7.5,"returnOnEquity":16.5,"analystRating":"1.5 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":1887.38,"targetHighPrice":2640.96,"targetLowPrice":1352.9,"dividendRate":0.62,"payoutRatio":0.46,"fiveYearAvgDividendYield":2.72,"exDividendDate":1773878400,"insiderHeldPercent":31.4,"institutionHeldPercent":46.9,"sharesOutstanding":216112791,"floatShares":151713093,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.37,"epsForward":1.87,"revenuePerShare":15.18,"bookValue":8.9,"officers":[{"age":68,"name":"H.E Said Samih Taleb Darwazah","title":"Chief Executive Officer"},{"age":67,"name":"Mr. Mazen Samih Taleb Darwazah","title":"Executive Vice Chairman & Deputy CEO of MENA"},{"age":53,"name":"Mr. Khalid Walid Hussni Al Nabilsi CPA","title":"Deputy CEO of North America and Europe & Director"},{"age":51,"name":"Mr. Areb  AL KURDI","title":"VP, Group Financial Controller & Acting CFO"},{"age":null,"name":"Ms. Patricia  Bousfield","title":"Chief Information Officer"},{"age":null,"name":"Mr. Guy  Featherstone","title":"Associate Director of Investor Relations"},{"age":null,"name":"Mr. Samuel  Park","title":"General Counsel"},{"age":60,"name":"Mr. Bassam Wael Rushdi Kanaan CFA, CPA","title":"Executive Vice President of Corporate Development and M&A"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.hikma.com","phone":"44 20 7399 2760"}}